Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 1862 · Optimizing Research Progress Hope And New Cures Act ·

ORPHAN Cures Act

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+3 −1Shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in paragraph (1), by adding at the end the following new subparagraph:(C) Treatment of former orphan drugs.— In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any …

  2. Carried out:

    by striking only one rare disease or condition and inserting one or more rare diseases or conditions; and

  3. Carried out:

    by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act).

§ 1320f–1(e)Qualifying single source drug(1)–(2)

Start of § 1320f–1 to (e)(1)(B)(i) unchanged ·

(ii) for which, as of the selected drug publication date with respect to such initial price applicability year, at least 11 years will have elapsed since the date of such licensure; and

(iii) that is not the reference product for any biological product that is licensed and marketed under section 262(k) of this title.

(C) [inserted: Treatment of former orphan drugs.—] [inserted: In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).]

(2) Treatment of authorized generic drugs

(A) In general In the case of a qualifying single source drug described in subparagraph (A) or (B) of paragraph (1) that is the listed drug (as such term is used in section 355(j) of title 21) or a product described in clause (ii) of subparagraph (B), with respect to an authorized generic drug, in applying the provisions of this part, such authorized generic drug and such listed drug or such product shall be treated as the same qualifying single source drug.

§ 1320f–1(e)(3)Exclusions(A)–(B)

(e)(2)(B) unchanged ·

(3) Exclusions In this part, the term “qualifying single source drug” does not include any of the following:

(A) Certain orphan drugs A drug that is designated as a drug for [struck: only ]one [inserted: or more ]rare [struck: disease][inserted: diseases] or [struck: condition][inserted: conditions] under section 360bb of title 21 and for which the only approved indication (or indications) is for [struck: such][inserted: one] [struck: disease][inserted: or] [inserted: more rare diseases ]or [struck: condition][inserted: conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act)].

(B) Low spend medicare drugs A drug or biological product with respect to which the total expenditures under parts B and D of subchapter XVIII, as determined by the Secretary in accordance with subsection (d)(3)(B)—

(i) with respect to initial price applicability year 2026, is less than, during the period beginning on June 1, 2022, and ending on May 31, 2023, $200,000,000;

Rest of § 1320f–1 unchanged ·

Step through the changes